MGM-15 (DiHydro-7-hydroxy Mitragynine) (DH-7OH-MIT) is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the South-East Asian tree kratom. MGM-15 was first reported in 2014. It is the 1,2-dihydro derivative of 7-hydroxymitragynine and shows higher potency as an agonist of the mu opioid receptor and delta opioid receptor compared to 7-hydroxymitragynine itself. MGM-15 has been sold as a designer drug since early 2025, initially in the USA. The 9-fluoro derivative of MGM-15 is known as MGM-16, and has even higher potency as an opioid agonist with around 240x the potency of morphine in animal studies.
]